On March 21, 2025, the Court held a Final Approval Hearing and granted the Final Judgement Approving the Settlement as well as the Order Approving the Plan of Allocation and the Order Awarding Attorneys' Fees, Litigation Expenses, as found on the Court Documents section of this website.
The information contained on this web page is only a summary of information presented in more detail in the Long-Form Notice of Pendency and Proposed Settlement of Class Action, (the “Notice”), which you can access by clicking Notice. Since this website is just a summary, you should review the Notice for additional information.
If you are a Settlement Class Member, your legal rights will be affected by this litigation whether you act or do not act.
Please read the Notice carefully.
If you purchased or otherwise acquired common stock issued by Talis Biomedical Corporation (“Talis” or the “Company”) pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s February 11, 2021 initial public offering between February 11, 2021 and August 11, 2021, inclusive, and were damaged thereby, you may be affected by this lawsuit.
How do I know if I am part of the Settlement?
The Settlement Class includes all persons or entities that purchased or otherwise acquired common stock issued by Talis pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s February 11, 2021 initial public offering between February 11, 2021 and August 11, 2021, inclusive (the “Settlement Class Period”), and were damaged thereby.
Please read Question Number 7 in the Notice for exceptions to inclusion in the Settlement Class.
How much will my payment be?
Your payment (if any) will depend on several things, including the total dollar amount of claims represented by the valid Proofs of Claim that Settlement Class Members submit; the number of shares of Talis common stock you purchased or acquired; how much you paid for those shares; when you purchased or acquired them; and if and when you sold your shares of Talis common stock and for how much. The Claims Administrator will apply the Plan of Allocation (detailed in Appendix A of the Notice) to calculate the amount of your Recognized Claim, and your payment (if any) will be a portion of the Net Settlement Fund equal to your Recognized Claim divided by the total of all Authorized Claimants’ Recognized Claims.
To qualify for payment, you must be an eligible Settlement Class Member, send in a timely and valid Proof of Claim, and properly document your claim as requested in the Proof of Claim.
The Settlement Hearing
On March 21, 2025, the Court held a Final Approval Hearing and granted the Final Judgement Approving the Settlement as well as the Order Approving the Plan of Allocation and the Order Awarding Attorneys' Fees, Litigation Expenses, as found on the Court Documents section of this website.
Further Information
For more details regarding this Settlement, please reference the documents filed in the case under the Court Documents section of this website. You may also contact the Claims Administrator for further information.
Claims Administrator:
Talis Biomedical Corporation Securities Litigation
c/o A.B. Data, Ltd.
P.O. Box 173064
Milwaukee, WI 53217
Telephone: 1-877-331-0411
Email: info@TalisSecuritiesLitigation.com
Lead Counsel:
Evan A. Kubota
Bleichmar Fonti & Auld LLP
300 Park Avenue, Suite 1301
New York, NY 10022
Telephone: 1-888-879-9418
Email: TalisSettlement@bfalaw.com